A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study
to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of
CM326 in patients with chronic rhinosinusitis with nasal polyps.
The study consists of 3 periods, a up-to-4-week Screening Period, a 12-week Treatment Period
and a 12-week Safety Follow-up Period.